Functional characterization of Candida albicans Hos2 histone deacetylase

F1000Research

Volumn 2, Issue , 2014, Pages

  Karthikeyan, G ^a   Paul Satyaseela, Maneesh ^a,b   Dhatchana Moorthy, Nachiappan ^a   Gopalaswamy, Radha ^a   Narayanan, Shridhar ^a,c  

^a R and D Center   (India)

^b Samrud Foundation for Health andResearch   (India)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ENTINOSTAT; HISTONE DEACETYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN HOS2; RESVERATROL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DEACETYLATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; FUNGAL GENE; FUNGAL GENOME; GENE EXPRESSION REGULATION; HIGH THROUGHPUT SCREENING; HOS2 GENE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION;

EID: 84914811793     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.2-238.v3     Document Type: Article

References (37)

1. Odds FC: Candida and candidosis: a review and bibliography: Bailliere Tindall;1988. Reference Source
2. Pfaller MA Diekema DJ Jones RN: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and In vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39(9):3254-3259. 11526159 10.1128/JCM.39.9.3254-3259.2001 88327
3. Fera MT La Camera E De Sarro A: New triazoles and echinocandins: mode of action, In vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009;7(8):981-998. 19803707 10.1586/eri.09.67
4. Sanglard D Ischer F Koymans L: Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998;42(2):241-253. 9527767 105395
5. White TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother. 1997;41(7):1488-1494. 9210671 163945
6. Song JL Harry JB Eastman RT: The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother. 2004;48(4):1136-1144. 15047513 10.1128/AAC.48.4.1136-1144.2004 375326
7. Sanglard D Kuchler K Ischer F: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995;39(11):2378-2386. 8585712 10.1128/AAC.39.11.2378 162951
8. Albertson GD Niimi M Cannon RD: Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother. 1996;40(12):2835-2841. 9124851 163632
9. Marr KA Lyons CN Rustad TR: Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother. 1998;42(10):2584-2589. 9756759 105901
10. Clayton AL Hazzalin CA Mahadevan LC: Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell. 2006;23(3):289-296. 16885019 10.1016/j.molcel.2006.06.017
11. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351-1356. 17322921 10.1038/sj.onc.1210204
12. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc.). 2009;45(11):787-795. 20126671 10.1358/dot.2009.45.11.1437052
13. Duvic M Vu J: Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics. 2007;1(4):377-392. 19707308 2721288
14. Dokmanovic M Clarke C Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5(10):981-989. 17951399 10.1158/1541-7786.MCR-07-0324
15. Mai A: The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets. 2007;11(6):835-851. 17504020 10.1517/14728222.11.6.835
16. Riester D Hildmann C Schwienhorst A: Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol. 2007;75(3):499-514. 17377788 10.1007/s00253-007-0912-1
17. Smith WL Edlind TD: Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother. 2002;46(11):3532-3539. 12384361 10.1128/AAC.46.11.3532-3539.2002 128736
18. Pfaller MA Messer SA Georgopapadakou N: Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47(12):3797-3804. 19794038 10.1128/JCM.00618-09 2786684
19. Simonetti G Passariello C Rotili D: Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans. FEMS Yeast Res. 2007;7(8):1371-1380. 17627775 10.1111/j.1567-1364.2007.00276.x
20. Wang A Kurdistani SK Grunstein M: Requirement of Hos2 histone deacetylase for gene activity in yeast. Science. 2002;298(5597):1412-1414. 12434058 10.1126/science.1077790
21. Hnisz D Schwarzmuller T Kuchler K: Transcriptional loops meet chromatin: a dual-layer network controls white-opaque switching in Candida albicans. Mol Microbiol. 2009;74(1):1-15. 19555456 10.1111/j.1365-2958.2009.06772.x 2764112
22. Hnisz D Majer O Frohner IE: The Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of Candida albicans. PLoS Pathog. 2010;6(5):e1000889. 20485517 10.1371/journal.ppat.1000889 2869326
23. Inglis DO Arnaud MB Binkley J: Candida Genome Database. Reference Source
24. Wurtele H Tsao S Lepine G: Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat Med. 2010;16(7):774-780. 20601951 10.1038/nm.2175
25. Gertz M Nguyen GT Fischer F: A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One. 2012;7(11):e49761. 23185430 10.1371/journal.pone.0049761 3504108
26. Fuller SA Takahashi M Hurrell JG: Immunization of Mice. Curr Protoc Mol Biol. John Wiley & Sons, Inc.;2001. 18265076 10.1002/0471142727.mb1104s18
27. Shechter D Dormann HL Allis CD: Extraction, purification and analysis of histones. Nat Protoc. 2007;2(6):1445-1457. 17545981 10.1038/nprot.2007.202
28. Yeast Nuclei Isolation. Reference Source
29. Knapp AR Ren C Su X: Quantitative profiling of histone post-translational modifications by stable isotope labeling. Methods. 2007;41(3):312-319. 17309842 10.1016/j.ymeth.2006.08.017 2572810
30. Wiren M Silverstein RA Sinha I: Genomewide analysis of nucleosome density histone acetylation and HDAC function in fission yeast. EMBO J. 2005;24(16):2906-2918. 16079916 10.1038/sj.emboj.7600758 1187943
31. Hnisz D Bardet AF Nobile CJ: A histone deacetylase adjusts transcription kinetics at coding sequences during Candida albicans morphogenesis. PLoS Genet. 2012;8(12):e1003118. 23236295 10.1371/journal.pgen.1003118 3516536
32. Zacchi LF Schulz WL Davis DA: HOS2 and HDA1 encode histone deacetylases with opposing roles in Candida albicans morphogenesis. PLoS One. 2010;5(8):e12171. 20730094 10.1371/journal.pone.0012171 2921335
33. Robyr D Suka Y Xenarios I: Microarray deacetylation maps determine genome-wide functions for yeast histone deacetylases. Cell. 2002;109(4):437-446. 12086601 10.1016/S0092-8674(02)00746-8
34. Finley KR Berman J: Microtubules in Candida albicans Hyphae Drive Nuclear Dynamics and Connect Cell Cycle Progression to Morphogenesis. Eukaryot Cell. 2005;4(10):1697-1711. 16215177 10.1128/EC.4.10.1697-1711.2005 1265902
35. Karthikeyan G Maneesh PS Nachiappan DM: Tubulin deacetylation and rHos2 protein blots. figshare. 2014. Data Source
36. Karthikeyan G Maneesh PS Nachiappan DM: Deacetylase activities of rHos2 and dose response curves of rHos2 inhibition by standard HDAC inhibitors. figshare. 2014. Data Source
37. Karthikeyan G Maneesh PS Nachiappan DM: Sirtuin assay of purified Hos2 preparations using resveratrol. figshare. 2014. Data Source